Do SGLT2 inhibitors help people over 80 who live with chronic kidney disease? The sglt2 inhibitors chronic kidney disease study 2026 gives a hopeful but careful answer: yes, starting this type of medicine was linked to fewer deaths and fewer serious kidney events over two years, but it was also linked to higher risks of certain heart problems and sudden kidney injury. In other words, age alone did not erase the benefit, yet the benefit did not come without trade-offs.
If you are over 80, or you care for someone who is, that short answer probably raises a longer list of questions. What exactly are these medicines? What does chronic kidney disease do to an older body? Who was actually studied, and who was left out? And what should a patient or a family ask at the next clinic visit? This article walks through the new research step by step, in plain language, so you can have a better-informed conversation with a doctor. It is general health information only, not medical advice, and it never replaces your own clinician's judgment about your health.
What the sglt2 inhibitors chronic kidney disease study 2026 actually found
The research was presented at ASN Kidney Week 2026, held October 22 to 25, 2026. ASN is the American Society of Nephrology, the professional body for kidney specialists, and its annual Kidney Week meeting is where new kidney research is shared with doctors and scientists from around the world. The study's full title was "Extending Benefit to the Oldest Old: Efficacy of SGLT2 Inhibitors in Older Adults with CKD."
Instead of running a brand-new clinical trial, the researchers looked back at electronic health records. They analyzed the records of 10,076 adults aged 80 years or older who had chronic kidney disease, and they followed what happened over a 2-year period after some of those patients started an SGLT2 inhibitor. Studies built on health records like this are sometimes called real-world studies, because they reflect the messy reality of everyday clinics rather than the tightly controlled conditions of a trial.
Over those two years, starting SGLT2 inhibitor therapy was linked to an 18% reduction in all-cause mortality. In plain terms, that means deaths from any cause were lower among those who started the medicine than among comparable patients who did not, by about eighteen percent in relative terms. It does not mean that eighteen out of every hundred people were saved, and it does not mean the medicine guarantees a longer life for any one person. Percentages like this describe patterns across a large group, and your own doctor is the person who can explain what they might mean for you.
The second headline finding was a 22% reduction in major adverse kidney events. That is a bundle of serious kidney outcomes that doctors track, such as a major worsening of kidney function or progression toward kidney failure. A reduction of that size, in people in their eighties and beyond, is striking, because kidney function usually becomes more fragile with age, not less. For families, the practical meaning is this: the kidneys of the oldest patients in this study did not simply keep declining at the same pace. On average, serious kidney trouble arrived less often.
Then came the part that keeps this story honest. The researchers found no significant effect on major adverse cardiovascular events overall. That is a combined measure of serious heart and blood-vessel problems, and across the whole group, the medicine did not clearly move it in either direction. Yet when the researchers looked closer, they found higher risks of specific cardiac events, including heart attacks and acute heart failure, as well as acute kidney injury. Acute kidney injury is a sudden, short-term drop in kidney function, which is different from the slow, long-term decline of chronic kidney disease. It can be triggered by illness, dehydration, or changes in medicines, and it needs prompt medical attention.
So the picture is genuinely mixed, and that matters. A medicine can protect the kidneys over time and still carry short-term risks that need watching. The study's corresponding author, Bernhard M. W. Schmidt, from the Department of Nephrology and Hypertension at Hannover Medical School in Germany, put it plainly: even the oldest and most vulnerable kidney patients can gain substantial benefits from this treatment, but these medicines may not be without risk in this age group, and patients need a careful, individualized risk-benefit assessment with close clinical monitoring. That sentence is really the heart of the whole study.
SGLT2 inhibitors explained in plain language
It helps to start with the kidneys themselves. You have two kidneys, each about the size of a fist, tucked toward the back of your abdomen. Their main job is to filter your blood, removing waste products and extra fluid, which leave the body as urine. They also help control blood pressure, balance salts and minerals in the blood, and support healthy red blood cells. When kidneys work well, you rarely notice them. When they struggle, the effects can ripple through the whole body.
SGLT2 stands for sodium-glucose cotransporter 2. That is a mouthful, but the idea is simple. Inside the kidney, tiny filters process the blood, and small proteins called transporters pull useful things back into the bloodstream before they are lost in urine. SGLT2 is one of those transporters, and its job is to reclaim glucose (blood sugar) and sodium from the fluid that will become urine. An SGLT2 inhibitor blocks that transporter, so more glucose and sodium leave the body in the urine instead of being pulled back.
These medicines were first developed for type 2 diabetes, because helping the body get rid of extra glucose lowers blood sugar. But doctors soon noticed something bigger. In large trials, people taking these medicines also had slower kidney decline and fewer hospital stays for heart failure, even when blood sugar was not the main issue. That is why SGLT2 inhibitors are now used as kidney medicines in their own right, and why a peer-reviewed review of their use in chronic kidney disease describes them as foundational agents for kidney, heart, and metabolic health in people with CKD, with or without type 2 diabetes.
Think of it this way. High pressure inside the kidney's tiny filters wears them out over time, a bit like high water pressure wearing out old pipes. By changing how salt and fluid move through the kidney, SGLT2 inhibitors appear to ease that pressure, which may slow the long-term damage. That is a simplified picture, and researchers are still studying the exact chain of effects, but it explains why a diabetes medicine ended up becoming a kidney medicine too.
Why would a diabetes medicine protect kidneys?
This is the question many patients ask first, and it is a fair one. If you do not have diabetes, why would a blood-sugar medicine be relevant to you? The answer is that the kidney-protecting effect does not seem to depend only on lowering blood sugar. The changes in pressure and fluid handling inside the kidney happen whether or not a person has diabetes, which is why later kidney trials included people without diabetes and still found benefit. Your clinician can tell you whether that applies to your situation, because kidney treatment always depends on the cause of your kidney disease and your other health conditions.
What SGLT2 inhibitors are not
They are not a cure for chronic kidney disease, and they do not replace dialysis for someone whose kidneys have already failed. They are not a substitute for blood pressure control, careful management of diabetes where it exists, or the other medicines a kidney patient may already take. And they are certainly not something to start or stop on the basis of a news article. Any change to a medicine, especially in an older adult who takes several medicines, needs a doctor or pharmacist to check for interactions and to plan monitoring.
What chronic kidney disease means for older adults
Chronic kidney disease, usually shortened to CKD, means the kidneys have been damaged or have not worked as well as they should for a long time, typically three months or more. It often develops slowly and quietly. Many people feel fine in the early stages, which is one reason it can go unnoticed until a routine blood or urine test picks it up. Doctors usually track it with two numbers: eGFR, which estimates how well the kidneys filter blood, and a urine test that looks for protein leaking into the urine, a sign that the filters are damaged.
Age is one of the strongest factors linked to CKD. Kidney function naturally declines somewhat as we get older, and the conditions that damage kidneys, such as high blood pressure and diabetes, also become more common with age. That does not mean kidney disease is simply "old age" and nothing can be done about it. It means older adults are the very people most likely to need kidney care, and yet, paradoxically, they are the people least likely to have been included in the trials that proved these treatments work.
For someone over 80, CKD rarely travels alone. Heart disease, diabetes, arthritis, frailty, and memory problems often sit alongside it, and a person may take many different medicines. That combination, which doctors call multimorbidity, makes treatment decisions more delicate. A medicine that helps the kidneys might affect blood pressure, fluid balance, or the risk of falls. A hospital stay for one problem can strain the kidneys and set off another. This is why kidney care for the oldest patients is never just about one lab number. It is about the whole person, their goals, and what kind of care they actually want.
There is also a very human side to this. At 82 or 87, a person may care less about a statistic and more about staying independent, avoiding hospital stays, keeping up with grandchildren, or simply feeling steady on their feet. Good kidney care should be judged by those goals too. A treatment that reduces serious kidney events is valuable, but only if it fits the person's life and does not create new burdens that outweigh the gain.
Who was studied, and who was not
The strength of the new study is its size and its age group. Ten thousand and seventy-six people is a large group, and every one of them was at least 80 years old with chronic kidney disease. That is exactly the population that earlier research tended to skip. Schmidt himself noted that very elderly people are historically underrepresented in, or systematically excluded from, large randomized controlled trials because of multimorbidity and frailty. By using real-world health records, his team addressed what he called a crucial blind spot in the medical literature.
That real-world design is both a strength and a weakness, and readers should understand both sides. On the plus side, the patients looked like real clinic patients, with all their complexity intact. On the minus side, this was an observational study, not a randomized trial. In a randomized trial, patients are assigned by chance to treatment or no treatment, which helps balance out hidden differences between the groups. In a records study, doctors chose who got the medicine and who did not, and those choices may reflect differences in health that the researchers could not fully measure. That is why the study shows a link, or association, between starting the medicine and better outcomes, but it does not by itself prove that the medicine caused those outcomes.
Why older patients are often missing from trials
Trials often exclude people with many health problems, people who take many medicines, or people who might struggle to attend frequent study visits. Those rules are meant to keep trials clean and safe, but they quietly filter out the oldest and frailest patients. The result is a strange gap: the people most likely to need a treatment in real life are the least studied. Real-world record studies like this one help fill that gap, but they cannot fully replace a randomized trial. Ideally, future trials will include more patients over 80 from the start, so doctors do not have to guess.
What we do not know about the participants
The published summary of the study does not give a detailed breakdown of every participant's kidney stage, diabetes status, or other medicines, and it does not report exact risk figures for each individual side effect. That is normal for a conference presentation, which is a shorter summary than a full journal article, but it means readers should be cautious about over-reading the results. The 18% and 22% figures are the headline relative reductions over two years. They are not promises for any individual, and the higher risks of heart attacks, acute heart failure, and acute kidney injury were reported without precise percentages in the summary available so far. If a fuller paper appears later, those details may sharpen the picture.
The benefits and risks at a glance
It is easy to get lost in percentages, so here is the whole story in one table. Keep the last column in mind: every row needs a conversation with a clinician, because the same medicine can look very different for two people of the same age.
| What the study looked at | What was found over 2 years | What it means in plain language |
|---|---|---|
| Deaths from any cause | 18% lower among those who started an SGLT2 inhibitor | Fewer deaths overall in the treated group, in relative terms |
| Major adverse kidney events | 22% lower among those who started an SGLT2 inhibitor | Serious kidney worsening happened less often |
| Major adverse cardiovascular events overall | No significant effect | No clear overall change in combined serious heart and vessel events |
| Specific cardiac events | Higher risks reported, including heart attacks and acute heart failure | Some individual heart problems appeared more often, needing close monitoring |
| Acute kidney injury | Higher risk reported | Sudden short-term kidney drops appeared more often, needing prompt care |
Notice the tension in that table. The kidneys did better overall, yet sudden kidney injury was more common. How can both be true? One explanation doctors often discuss is that short-term dips in kidney function can happen when fluid balance shifts, during illness, or when other medicines change, even while the long-term trend of kidney decline slows down. That does not make the risk unimportant. It makes monitoring important, especially in the first weeks after starting a medicine and during any illness that causes vomiting, diarrhea, fever, or poor fluid intake.
There is another caution worth stating clearly. Older adults are also more vulnerable to dehydration, dizziness, and low blood pressure, because SGLT2 inhibitors increase the amount of fluid and salt leaving in urine. That effect is part of how the medicines work, but in a frail older adult, too much fluid loss can lead to falls or confusion. Families sometimes notice these changes before a doctor does: a parent drinking less, eating less, feeling lightheaded on standing, or making more frequent trips to the bathroom at night. Those observations are worth reporting, not dismissing.
What the sglt2 inhibitors chronic kidney disease study 2026 did NOT show
Good science is as much about what was not shown as what was shown, so let us be precise here. First, the study did not show that SGLT2 inhibitors prevent heart attacks or heart failure in people over 80. In fact, the overall cardiovascular result was neutral, and specific cardiac risks were higher. Anyone who reads this study as "great news for the heart" has misread it. The heart story for the oldest patients is unresolved and needs more research.
Second, the study did not show that every person over 80 with CKD should take this medicine. It studied people who started the medicine in routine care, and it compared them with others using health records. It did not test a one-size-fits-all rule, and it did not weigh each person's other illnesses, medicines, or personal goals. A treatment that helps on average can still be wrong for a particular person, and only their own clinician, who knows their full history, can make that call.
Third, the study did not test doses, and it did not compare one SGLT2 inhibitor with another. This article deliberately names no specific medicine and gives no dose, because the conference summary did not support that level of detail and because dosing is a clinical decision, not a news detail. If you read other articles that name a product or suggest a dose for older patients, treat that with caution and check it against your own prescription and your doctor's advice.
Fourth, the study did not follow patients for a lifetime. Two years is a meaningful window, especially at advanced ages, but it cannot answer questions about five-year or ten-year effects, or about what happens when a medicine is stopped. Long-term follow-up and fuller published results will matter, and this article's conclusions should be revisited when they appear.
Finally, and most importantly, an observational link is not proof of cause. It is possible that some of the difference between the groups came from differences in the patients themselves, not from the medicine alone. That does not make the study useless. Far from it. In a population that trials have ignored, a large real-world signal like this is genuinely valuable. It just means the right response is careful, individual assessment, not a rush to prescribe for everyone.
Questions patients and families can ask a clinician
If you or a loved one has CKD and is over 80, the new study gives you something concrete to talk about at the next appointment. You do not need to understand every statistic to ask good questions. Here are some that kidney specialists would recognize as sensible, and that can help a doctor tailor the conversation to you.
- Given my kidney stage, my heart history, and my other medicines, could an SGLT2 inhibitor be an option for me, or are there reasons it would not suit me?
- What would we monitor if I started this kind of medicine, and how often would we check my kidney function, blood pressure, and fluid balance?
- What symptoms should I watch for at home, and when should I call the clinic rather than waiting for the next visit?
- How would this medicine fit with the medicines I already take, especially water pills, blood pressure medicines, and diabetes medicines?
- What should I do if I become ill with vomiting, diarrhea, or fever, or if I stop eating and drinking normally for a day or two?
- If I have had heart failure or a heart attack before, how does that change the balance of benefits and risks for me?
- What are my own goals for treatment, and how do we weigh living longer against avoiding hospital stays and keeping daily life comfortable?
Families can help by bringing a complete, up-to-date list of medicines, including over-the-counter products and supplements, and by noting any recent falls, dizziness, or changes in appetite, sleep, or bathroom habits. Doctors make better decisions with that kind of everyday detail than with lab numbers alone. And if a parent or grandparent struggles to hear, remember, or travel to appointments, ask the clinic what support is available, such as written summaries, pharmacist reviews, or telehealth check-ins where appropriate.
Everyday habits that still matter for kidney health
No medicine works in isolation, and kidney health is no exception. While the sglt2 inhibitors chronic kidney disease study 2026 focused on medicines, the habits below are the everyday foundations that kidney specialists commonly emphasize for older adults. They do not replace medical treatment, and they are not a substitute for a doctor's plan, but they are the background that lets any treatment work at its best.
First, take medicines exactly as prescribed, and never start or stop a prescription medicine because of something you read online. If a medicine causes side effects, or if cost or confusion makes it hard to take, tell the doctor or pharmacist rather than quietly skipping doses. Pharmacists can often simplify a regimen, check for interactions, and explain what each tablet is for, which is a real help when a person takes many medicines.
Second, keep blood pressure and blood sugar in the ranges your clinician has set for you. Both are major drivers of kidney damage over time, and both are worth tracking at home if your doctor asks you to. A simple home blood pressure log, brought to appointments, can reveal patterns that a single clinic reading misses.
Third, stay as active as your body allows. Gentle, regular movement supports the heart, the blood vessels, and general strength, all of which matter for kidney health too. Even short, regular walks count, and they also help with sleep, mood, and balance. For more on why small amounts of movement matter, see our earlier look at how low daily step counts were linked to dementia and stroke risk in a 2026 study, which is a useful reminder that steps are about far more than fitness.
Fourth, pay attention to food and fluid without turning eating into a source of stress. Many kidney patients are advised to watch salt intake, and some need guidance on potassium, phosphate, or protein, but those needs vary a lot from person to person. A dietitian who understands kidney disease can tailor advice to your lab results, which is far safer than following a generic kidney diet from the internet. Drink enough fluid to stay hydrated, especially in hot weather or during illness, unless your clinician has set a fluid limit for you.
Fifth, do not smoke, and keep alcohol within the limits your doctor advises. Both can strain the heart and blood vessels, and smoking in particular accelerates kidney decline. If quitting feels hard, ask for help rather than facing it alone. Support makes a real difference at any age.
Finally, keep up with routine checks. Kidney disease is quiet, so regular blood and urine tests are how doctors catch changes early. If you have diabetes, its management matters for the kidneys too, and our earlier article on weight-loss surgery and diabetes remission research shows how closely diabetes and long-term health are connected, even though surgery is a very different topic from everyday kidney care.
Heart and kidneys: why the two stories are linked
One reason the new study's heart findings deserve attention is that the heart and kidneys depend on each other. When kidneys weaken, fluid and salts can build up, blood pressure can rise, and the heart has to work harder. When the heart weakens, the kidneys may receive less blood flow, which can worsen kidney function. Doctors sometimes call this a two-way relationship, and it is why a medicine that affects one organ often affects the other.
That connection is also why heart risk deserves its own conversation in kidney care, at every age. For context on how heart risk can rise in specific groups, readers may find our earlier article on premature menopause and heart disease risk interesting, since it explores another situation where heart risk was higher than many people expected. The details differ from the new kidney study, but the lesson rhymes: risk is rarely obvious, and it is worth asking about rather than assuming.
For patients over 80, the heart-kidney link also shapes what monitoring looks like. A doctor may want to know about breathlessness, swelling in the legs, chest discomfort, unusual tiredness, or waking up short of breath at night. Those symptoms can have many causes, and they do not automatically mean a medicine is at fault, but they are exactly the kind of changes that should be reported promptly, not saved for a routine visit months later.
Frequently asked questions
Are SGLT2 inhibitors safe for people over 80?
The new study suggests that, on average, starting an SGLT2 inhibitor was linked to fewer deaths and fewer serious kidney events in people over 80 with CKD, but it also found higher risks of certain heart events and acute kidney injury. That is not a simple "safe" or "unsafe" verdict. Safety in this age group depends on the individual's heart history, kidney function, other medicines, frailty, and how closely they can be monitored. The study's own message was individualized assessment and close monitoring, not a blanket reassurance.
Do SGLT2 inhibitors work for kidney disease if I do not have diabetes?
These medicines were first developed for type 2 diabetes, but their kidney-protective role is now recognized more broadly. A peer-reviewed review of SGLT2 inhibitor use in CKD notes that these medicines are recommended for patients with CKD with or without type 2 diabetes, and that earlier kidney trials included people without diabetes. Whether they suit a particular person without diabetes still depends on their kidney diagnosis, kidney function, and other conditions, so this is a question for their own clinician, not a general rule.
What side effects should older adults watch for?
The 2026 study flagged higher risks of heart attacks, acute heart failure, and acute kidney injury in its over-80 group. More generally, SGLT2 inhibitors increase urine output, which can lead to dehydration, dizziness, and low blood pressure, especially in older adults. Genital and urinary infections are also a known concern with this class of medicines. Any new symptom, such as burning on urination, unusual itching, severe dizziness, fainting, chest pain, breathlessness, or a sharp drop in urine output, should be reported to a clinician promptly. Never try to ride out a worrying symptom at home.
Should I ask my doctor about this study?
Yes, if you are over 80 and live with CKD, or if you care for someone who does, this study is worth mentioning at the next appointment. Bring the questions listed above, bring a full medicine list, and be ready to talk about your goals and concerns. A good conversation will not end with a yes or no on the spot. It will end with a plan: what to monitor, what to watch for, and when to review the decision again.
The bottom line for patients over 80 and their families
Here is where the story lands. The sglt2 inhibitors chronic kidney disease study 2026 fills an important gap by looking at the very patients that earlier trials tended to leave out: adults aged 80 and older with chronic kidney disease. In a large real-world analysis of 10,076 such patients followed for two years, starting an SGLT2 inhibitor was linked to an 18% reduction in deaths from any cause and a 22% reduction in major adverse kidney events. Those are meaningful numbers, and they challenge the assumption that the oldest patients are simply too old to benefit.
But the study also refuses to be a simple success story. There was no significant overall effect on major cardiovascular events, and the risks of specific heart problems and sudden kidney injury were higher. That combination, benefit on one side and risk on the other, is exactly why the researchers called for careful, individualized assessment and close monitoring. It is also why this article keeps returning to the same advice: talk to your own doctor, bring your questions, and make the decision together.
If there is one idea to carry away, it is this. Age should not automatically close the door on a treatment, but neither should a promising headline open it without thought. The oldest patients deserve the same careful, personal medicine as everyone else, perhaps more so, because their health is more complex and their margin for error is smaller. This study gives doctors and families better information for that conversation. What it cannot do is have the conversation for you.
Important note: this article is general health information only and is not medical advice. It does not tell any reader to start, stop, or change any medicine. If you have chronic kidney disease, or you care for someone who does, please discuss this research with a qualified doctor or pharmacist who knows the full medical history involved. If you notice worrying symptoms such as chest pain, severe breathlessness, fainting, or a sudden drop in urine output, seek medical attention promptly.
For readers who want to check the source of this story, the study was reported by Medical Dialogues coverage of the ASN Kidney Week 2026 research on SGLT2 inhibitors in CKD patients aged 80 and older, and background on how these medicines are used in kidney disease is available in this peer-reviewed review of SGLT2 inhibitor use in chronic kidney disease.